It used to be the “demon king”, but now it has become a money printer!
Covid-19 test Bull Stock Andon Health Co.Ltd(002432) , which has risen 12 times in two months, swiped the screen in the A-share market again.
On April 12, Andon Health Co.Ltd(002432) rushed to the top of the popularity list of stock bar by virtue of a performance forecast. The company expects a net profit of 14 billion yuan to 16 billion yuan in the first quarter, with a year-on-year increase of 36707% to 41966%. The sharp increase in performance is mainly due to the sharp increase in the demand for covid-19 antigen detection kit products in the United States.
Although the market had previously expected the growth of Andon Health Co.Ltd(002432) performance, such a rapid growth still exceeded the imagination of many investors. Stimulated by the above positive news, Andon Health Co.Ltd(002432) opened at the limit price on the same day. Although the trading was briefly opened, it was then blocked until the closing. The whole day turnover was 7.47 billion yuan, with a turnover rate of more than 21%, and the latest market value was 35.6 billion yuan.
Andon Health Co.Ltd(002432) performance soared, earning more than 14 billion yuan in the first quarter
On the morning of April 12, Andon Health Co.Ltd(002432) issued a performance forecast on the Shenzhen Stock Exchange. It is estimated that the net profit in the first quarter will be 14 billion yuan to 16 billion yuan, with a year-on-year increase of 3670743% to 4196563%. Deducting non net profit of 14 billion yuan to 16 billion yuan, an increase of 73845244% to 84395993% over the same period of the previous year.
For the reasons for the surge in performance, Andon Health Co.Ltd(002432) explained that the local demand for covid-19 antigen detection kit products has increased significantly due to the development of the epidemic in the United States. During the reporting period, ihealth US subsidiary of the company sold ihealth covid-19 antigen detection kit products through its own channels and Amazon platform, and signed major contracts and orders with customers. The increase in sales revenue of this product has made an important contribution to the company’s performance during the reporting period.
At the same time, Andon Health Co.Ltd(002432) also disclosed the performance express. In 2021, the company achieved a total operating revenue of 2.512 billion yuan, a year-on-year increase of 25.11%; The net profit attributable to the owners of the parent company was 913 million yuan, an increase of 276.87% over the previous year.
This means that Andon Health Co.Ltd(002432) the money earned in the first quarter of 2022 is more than 15 times that of 2021. Among the A-share listed companies that have disclosed the performance forecast of the first quarter, if compared according to the lower limit of net profit, the single quarter net profit of Andon Health Co.Ltd(002432) 14 billion yuan can rank third, second only to Cosco Shipping Holdings Co.Ltd(601919) the 27.6 billion yuan and Kweichow Moutai Co.Ltd(600519) the 16.6 billion yuan.
netizen: it’s the money printer
Andon Health Co.Ltd(002432) such explosive performance growth shocked many netizens. Some netizens said: “money printer, that’s right”. Some investors shouted: people should have soared last year! Some people also said, “you don’t have to do anything if you have interest for a year.”
Another netizen calculated: “the profit in a quarter is 15 billion, and the average profit per day is 170 million. It’s really a cow. If the profit is 50%, the turnover of Jiu’An should be 30 billion, equivalent to nearly 5 billion US dollars. It’s too cow.”
Some people can’t believe it: “it won’t be an oolong. Forget to make the decimal point.”. Another netizen said, is the sales written as profit? In response, some investors responded that you only saw large orders and didn’t put in Amazon’s small orders. In e-commerce, they were almost out of stock.
Some investors also remind that this is cyclical and short-term, and the stock price has responded in advance.
has increased 12 times in two months
it is worth mentioning that Andon Health Co.Ltd(002432) was once a bull stock in the A-share market
On November 7, 2021, Andon Health Co.Ltd(002432) announced that ihealth home covid-19 self-test kit, an American subsidiary, was authorized by FDA for emergency use; On November 15, Andon Health Co.Ltd(002432) also said on the interactive platform that the company’s covid-19 antigen home self-test OTC kit products have started large-scale production, and have been sold locally by its subsidiary ihealth in the United States at the beginning of last week. At present, the company’s monthly production capacity is 100 million people. It is estimated that by the beginning of 2022, the production capacity will increase to 200 million people per month.
Then the company’s share price soared. From November 15, 2021 to January 18, 2022, the share price of Andon Health Co.Ltd(002432) increased by more than 12 times, reaching a maximum of 88.88 yuan / share. During this period, Andon Health Co.Ltd(002432) was frequently questioned about “hyping the stock price”, and the company also received many attention letters issued by the Shenzhen Stock Exchange.
From mid January 2022, Andon Health Co.Ltd(002432) successively disclosed the signing of large orders for covid-19 antigen detection products in the United States. On January 14, Andon Health Co.Ltd(002432) announced that the US subsidiary and ACC signed a purchase contract on January 13 local time to sell ihealth kit products to them, with a total contract price tax of US $1.275 billion (including freight), about RMB 8.102 billion. On January 26, the two sides signed the change contract on the purchase contract. On the basis of the purchase of 250 million ihealth kit products in the original contract, 104 million ihealth kit products were purchased, and the total contract amount increased from US $1.275 billion to US $1.775 billion (about RMB 11.226 billion).
As of April 1, ACC has paid a total of US $1.1 billion, or about RMB 7.047 billion, to the company’s US subsidiaries. All the above payments have been received. According to this calculation, Andon Health Co.Ltd(002432) U.S. subsidiary still has US $665 million of payment outstanding Andon Health Co.Ltd(002432) said that the above situation was in line with the delivery and payment arrangements stipulated in the contract, and the contract was in the process of normal performance.
However, Andon Health Co.Ltd(002432) covid-19 self test kit has not yet entered the Chinese market. Since China liberalized antigen self-test in mid March, covid-19 antigen test products of more than 20 companies, including Guangzhou Wondfo Biotech Co.Ltd(300482) , Beijing Hotgen Biotech Co.Ltd(688068) , Zhejiang Orient Gene Biotech Co.Ltd(688298) have been approved for listing.
Guolian Securities Co.Ltd(601456) pointed out that from the perspective of epidemic control, nucleic acid and antigen detection will help to achieve the goal of dynamic clearing. It is expected that the demand for nucleic acid detection capacity and antigen detection products in China will continue to increase in the future.
